Market Research Logo

Genital Herpes - Pipeline Review, H2 2018

Genital Herpes - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2018, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 17 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Genital Herpes - Overview
Genital Herpes - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Genital Herpes - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Genital Herpes - Companies Involved in Therapeutics Development
Abivax SA
Admedus Ltd
AiCuris GmbH & Co KG
Auritec Pharmaceuticals Inc
Biomere LLC
BlueWillow Biologics Inc
GenVec Inc
Immune Design Corp
NanoViricides Inc
Profectus BioSciences Inc
Redbiotec AG
Sanofi Pasteur SA
Stabilitech Biopharma Ltd
Starpharma Holdings Ltd
Vaccibody AS
Vical Inc
Genital Herpes - Drug Profiles
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acyclovir SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GV-2207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus [type 1, 2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSV-529 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pritelivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Profavax HSV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Profavax HSV-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLV-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Genital Herpes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Theravax HSV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Theravax HSV-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triptorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCLHM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMTX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Genital Herpes - Dormant Projects
Genital Herpes - Discontinued Products
Genital Herpes - Product Development Milestones
Featured News & Press Releases
May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study
Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data
Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
Feb 03, 2016: Model helps decide drug dose for clinical testing
Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine
Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences
Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection
Oct 02, 2014: Admedus Announces Further Data From Herpes Simplex Vaccine Trial
Feb 03, 2014: Admedus Herpes Interim Phase I Results
Oct 17, 2013: ALLIED HERPES PHASE I TRIAL PROGRESS UPDATE
Jun 19, 2013: Allied Healthcare Receives Ethical Approval To Commence Phase I Clinical Trial Of HSV-2 Vaccine
Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II Trial For Herpes Drug Pritelivir
Nov 27, 2012: AiCuris Starts Second Clinical Efficacy Trial With pritelivir
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Genital Herpes, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Genital Herpes - Pipeline by Abivax SA, H2 2018
Genital Herpes - Pipeline by Admedus Ltd, H2 2018
Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H2 2018
Genital Herpes - Pipeline by Auritec Pharmaceuticals Inc, H2 2018
Genital Herpes - Pipeline by Biomere LLC, H2 2018
Genital Herpes - Pipeline by BlueWillow Biologics Inc, H2 2018
Genital Herpes - Pipeline by GenVec Inc, H2 2018
Genital Herpes - Pipeline by Immune Design Corp, H2 2018
Genital Herpes - Pipeline by NanoViricides Inc, H2 2018
Genital Herpes - Pipeline by Profectus BioSciences Inc, H2 2018
Genital Herpes - Pipeline by Redbiotec AG, H2 2018
Genital Herpes - Pipeline by Sanofi Pasteur SA, H2 2018
Genital Herpes - Pipeline by Stabilitech Biopharma Ltd, H2 2018
Genital Herpes - Pipeline by Starpharma Holdings Ltd, H2 2018
Genital Herpes - Pipeline by Vaccibody AS, H2 2018
Genital Herpes - Pipeline by Vical Inc, H2 2018
Genital Herpes - Dormant Projects, H2 2018
Genital Herpes - Dormant Projects, H2 2018 (Contd..1), H2 2018
Genital Herpes - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Genital Herpes, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report